France OKs Early Access To Tecentriq For SCLC Pending EU Approval

Tecentriq has become the second authorized medicine to be made available for an unapproved indication under modifications to France’s early access program. Patients with small cell lung cancer can now be given the product pending EU approval of its use in this condition.

XRay
France is making Tecentriq available for small cell lung cancer • Source: Shutterstock

The French regulatory agency ANSM has approved an early access program for Roche’s checkpoint inhibitor Tecentriq (atezolizumab) as a first-line treatment for patients with advanced small cell lung cancer (SCLC).

Tecentriq is being made available for this unapproved indication under a new provision introduced by the 2019 social security financing...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Market Access

More from Pink Sheet